BACKGROUND:Antiretroviral (ARV) prophylaxis effectively reduces mother-to-child transmission of human immunodeficiency virus type 1 (HIV). However, it is unclear whether stopping ARVs after breastfeeding cessation affects maternal HIV disease progression. We assessed 18-24-month postpartum disease progression risk among women in a randomized trial assessing efficacy and safety of prophylactic maternal ARVs. METHODS:From 2005 to 2008, HIV-infected pregnant women with CD4(+) counts of 200-500/mm(3) were randomized to receive either triple ARV (zidovudine, lamivudine, and lopinavir/ritonavir during pregnancy and breastfeeding) or AZT/sdNVP (zidovudine until delivery with single-dose nevirapine without postpartum prophylaxis). Maternal disease progression was defined as the combined endpoint of death, World Health Organization clinical stage 4 disease, or CD4(+) counts of <200/mm(3). RESULTS: Among 824 randomized women, 789 had at least 1 study visit after cessation of ARV prophylaxis. Following delivery, progression risk up to 24 months postpartum in the triple ARV arm was significantly lower than in the AZT/sdNVP arm (15.7% vs 28.3%; P = .001), but the risks of progression after cessation of ARV prophylaxis (rather than after delivery) were not different (15.0% vs 13.8% 18 months after ARV cessation). Among women with CD4(+) counts of 200-349/mm(3) at enrollment, 24.0% (95% confidence interval [CI], 15.7-35.5) progressed with triple ARV, and 23.0% (95% CI, 17.8-29.5) progressed with AZT/sdNVP, whereas few women in either arm (<5%) with initial CD4(+) counts of ≥350/mm(3) progressed. CONCLUSIONS: Interrupting prolonged triple ARV prophylaxis had no effect on HIV progression following cessation (compared with AZT/sdNVP). However, women on triple ARV prophylaxis had lower progression risk during the time on triple ARV. Given the high rate of progression among women with CD4(+) cells of <350/mm(3), ARVs should not be discontinued in this group. CLINICAL TRIALS REGISTRATION: ISRCTN71468410.
RCT Entities:
BACKGROUND: Antiretroviral (ARV) prophylaxis effectively reduces mother-to-child transmission of human immunodeficiency virus type 1 (HIV). However, it is unclear whether stopping ARVs after breastfeeding cessation affects maternal HIV disease progression. We assessed 18-24-month postpartum disease progression risk among women in a randomized trial assessing efficacy and safety of prophylactic maternal ARVs. METHODS: From 2005 to 2008, HIV-infected pregnant women with CD4(+) counts of 200-500/mm(3) were randomized to receive either triple ARV (zidovudine, lamivudine, and lopinavir/ritonavir during pregnancy and breastfeeding) or AZT/sdNVP (zidovudine until delivery with single-dose nevirapine without postpartum prophylaxis). Maternal disease progression was defined as the combined endpoint of death, World Health Organization clinical stage 4 disease, or CD4(+) counts of <200/mm(3). RESULTS: Among 824 randomized women, 789 had at least 1 study visit after cessation of ARV prophylaxis. Following delivery, progression risk up to 24 months postpartum in the triple ARV arm was significantly lower than in the AZT/sdNVP arm (15.7% vs 28.3%; P = .001), but the risks of progression after cessation of ARV prophylaxis (rather than after delivery) were not different (15.0% vs 13.8% 18 months after ARV cessation). Among women with CD4(+) counts of 200-349/mm(3) at enrollment, 24.0% (95% confidence interval [CI], 15.7-35.5) progressed with triple ARV, and 23.0% (95% CI, 17.8-29.5) progressed with AZT/sdNVP, whereas few women in either arm (<5%) with initial CD4(+) counts of ≥350/mm(3) progressed. CONCLUSIONS: Interrupting prolonged triple ARV prophylaxis had no effect on HIV progression following cessation (compared with AZT/sdNVP). However, women on triple ARV prophylaxis had lower progression risk during the time on triple ARV. Given the high rate of progression among women with CD4(+) cells of <350/mm(3), ARVs should not be discontinued in this group. CLINICAL TRIALS REGISTRATION: ISRCTN71468410.
Authors: Louise Kuhn; Grace M Aldrovandi; Moses Sinkala; Chipepo Kankasa; Mwiya Mwiya; Donald M Thea Journal: AIDS Date: 2010-06-01 Impact factor: 4.177
Authors: D N Burns; S Landesman; H Minkoff; D J Wright; D Waters; R M Mitchell; A Rubinstein; A Willoughby; J J Goedert Journal: Am J Obstet Gynecol Date: 1998-02 Impact factor: 8.661
Authors: Arlene D Bardeguez; David E Shapiro; Lynne M Mofenson; Robert Coombs; Lisa M Frenkel; Mary Glenn Fowler; Sharon Huang; Rhoda S Sperling; Bethann Cunningham; Jorge Gandia; Robert Maupin; Carmen D Zorrilla; Theodore Jones; Mary Jo O'Sullivan Journal: J Acquir Immune Defic Syndr Date: 2003-02-01 Impact factor: 3.731
Authors: Howard Minkoff; Ron Hershow; D Heather Watts; Margaret Frederick; Irene Cheng; Ruth Tuomala; Jane Pitt; Carmen D Zorrilla; Hunter Hammill; Samuel K Adeniyi-Jones; Bruce Thompson Journal: Am J Obstet Gynecol Date: 2003-08 Impact factor: 8.661
Authors: D Heather Watts; John Lambert; E Richard Stiehm; D Robert Harris; James Bethel; Lynne Mofenson; William A Meyer; Bonnie Mathieson; Mary Glen Fowler; George Nemo Journal: J Acquir Immune Defic Syndr Date: 2003-08-15 Impact factor: 3.731
Authors: W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245
Authors: Risa M Hoffman; Konstantia Nadia Angelidou; Sean S Brummel; Friday Saidi; Avy Violari; Dingase Dula; Vidya Mave; Lee Fairlie; Gerhard Theron; Moreen Kamateeka; Tsungai Chipato; Benjamin H Chi; Lynda Stranix-Chibanda; Teacler Nematadzira; Dhayendre Moodley; Debika Bhattacharya; Amita Gupta; Anne Coletti; James A McIntyre; Karin L Klingman; Nahida Chakhtoura; David E Shapiro; Mary Glenn Fowler; Judith S Currier Journal: HIV Clin Trials Date: 2018-12
Authors: Andreas D Haas; Lyson Tenthani; Malango T Msukwa; Kali Tal; Andreas Jahn; Oliver J Gadabu; Adrian Spoerri; Frank Chimbwandira; Joep J van Oosterhout; Olivia Keiser Journal: Lancet HIV Date: 2016-03-09 Impact factor: 12.767
Authors: Aditya S Khanna; Sarah T Roberts; Susan Cassels; Roger Ying; Grace John-Stewart; Steven M Goodreau; Jared M Baeten; Pamela M Murnane; Connie Celum; Ruanne V Barnabas Journal: PLoS One Date: 2015-08-11 Impact factor: 3.240